BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

6 articles for O Callaghan

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.EBI
Astex Therapeutics
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.EBI
Astrazeneca Pharmaceuticals
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.EBI
Astex Therapeutics
Sulfoximine substituted quinazolines for pharmaceutical compositionsBDB
Evotec Internatonal
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.BDB
U. 109
Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.BDB
Bristol-Myers Squibb Pharmaceutical Research Institute